KR20180108811A - 부비강 질환 및 장애의 치료를 위한 조성물 및 방법 - Google Patents

부비강 질환 및 장애의 치료를 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20180108811A
KR20180108811A KR1020187025908A KR20187025908A KR20180108811A KR 20180108811 A KR20180108811 A KR 20180108811A KR 1020187025908 A KR1020187025908 A KR 1020187025908A KR 20187025908 A KR20187025908 A KR 20187025908A KR 20180108811 A KR20180108811 A KR 20180108811A
Authority
KR
South Korea
Prior art keywords
flo
carrageenan
crs
kappa
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020187025908A
Other languages
English (en)
Korean (ko)
Inventor
샘 바바라트
Original Assignee
이엔티 테크놀로지스 피티와이 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016900553A external-priority patent/AU2016900553A0/en
Application filed by 이엔티 테크놀로지스 피티와이 리미티드 filed Critical 이엔티 테크놀로지스 피티와이 리미티드
Publication of KR20180108811A publication Critical patent/KR20180108811A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020187025908A 2016-02-17 2017-02-17 부비강 질환 및 장애의 치료를 위한 조성물 및 방법 Withdrawn KR20180108811A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2016900553 2016-02-17
AU2016900553A AU2016900553A0 (en) 2016-02-17 Compositions and Methods for the Treatment of Sinus Diseases and Disorders
PCT/AU2017/050144 WO2017139854A1 (en) 2016-02-17 2017-02-17 Compositions and methods for the treatment of sinus disease and disorders

Publications (1)

Publication Number Publication Date
KR20180108811A true KR20180108811A (ko) 2018-10-04

Family

ID=59624790

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187025908A Withdrawn KR20180108811A (ko) 2016-02-17 2017-02-17 부비강 질환 및 장애의 치료를 위한 조성물 및 방법

Country Status (14)

Country Link
US (1) US11357791B2 (https=)
EP (1) EP3416655A4 (https=)
JP (1) JP2019505538A (https=)
KR (1) KR20180108811A (https=)
CN (1) CN108697731A (https=)
AU (1) AU2017220396B2 (https=)
BR (1) BR112018016651A2 (https=)
CA (1) CA3013942C (https=)
HK (1) HK1258884A1 (https=)
IL (1) IL261134B2 (https=)
MY (1) MY200434A (https=)
SG (1) SG11201806835SA (https=)
WO (1) WO2017139854A1 (https=)
ZA (1) ZA201806103B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1258884A1 (zh) 2016-02-17 2019-11-22 Ent Technologies Pty Ltd 用於治疗窦疾病和病症的组合物和方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3563194B2 (ja) * 1996-03-15 2004-09-08 株式会社ノエビア 塩化ナトリウム含有ゲル組成物及びその製造方法
JPH11189533A (ja) * 1997-12-25 1999-07-13 Taisho Pharmaceut Co Ltd 点眼薬
US6214376B1 (en) * 1998-08-25 2001-04-10 Banner Pharmacaps, Inc. Non-gelatin substitutes for oral delivery capsules, their composition and process of manufacture
US6518244B2 (en) * 2000-03-09 2003-02-11 Intimax Corporation Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof
JP2002302448A (ja) * 2001-04-02 2002-10-18 Shiseido Co Ltd 皮膚外用剤
CN1491724A (zh) * 2003-09-02 2004-04-28 无锡杰西医药科技有限公司 一种适用于青光眼治疗的成胶增稠用多糖系统
EP1930015A1 (en) * 2006-12-05 2008-06-11 Marinomed Biotechnologie GmbH Use of carrageenan for treating rhinovirus infections
US20080317791A1 (en) * 2007-06-25 2008-12-25 Cp Kelco U.S., Inc. Kappa Carrageenan
JP2011219412A (ja) * 2010-04-09 2011-11-04 Saisentan Igaku Kenkyusho:Kk 緑内障の視野改善治療薬
AU2012212385B2 (en) * 2011-02-02 2015-01-15 Ent Technologies Pty Ltd Compositions and methods for the treatment of nasal passages
WO2012126777A1 (en) * 2011-03-18 2012-09-27 Marinomed Biotechnologie Gmbh Inhibition of neuraminidase activity
RU2015136769A (ru) * 2013-02-05 2017-03-13 Дзе Попьюлейшн Каунсил, Инк. Внутривагинальное кольцо для доставки уникальных комбинаций противомикробных композиций
CA2932237C (en) * 2013-12-03 2022-12-13 Gerolymatos International S.A. Ionic aqueous compositions comprising sulfated polysaccharides
EP3099292A1 (en) * 2014-01-28 2016-12-07 Resdevco Research and Development Co. Ltd. Composition comprising xylitol and cholecalciferol for topical treatment of skin and mucous membranes
DE102015110674A1 (de) 2015-07-02 2017-01-05 Sms Group Gmbh Umbausystem für einen Elektrolichtbogenofen (EAF)
MA43155A (fr) * 2015-07-14 2018-09-12 Marinomed Biotech Ag Composition de déblocage de nez congestionné présentant une activité antivirale
HK1258884A1 (zh) 2016-02-17 2019-11-22 Ent Technologies Pty Ltd 用於治疗窦疾病和病症的组合物和方法

Also Published As

Publication number Publication date
IL261134B (en) 2022-11-01
EP3416655A4 (en) 2019-11-20
US11357791B2 (en) 2022-06-14
IL261134A (en) 2018-10-31
CA3013942A1 (en) 2017-08-24
SG11201806835SA (en) 2018-09-27
BR112018016651A2 (pt) 2018-12-26
ZA201806103B (en) 2019-07-31
JP2019505538A (ja) 2019-02-28
HK1258884A1 (zh) 2019-11-22
IL261134B2 (en) 2023-03-01
EP3416655A1 (en) 2018-12-26
MY200434A (en) 2023-12-26
US20200276226A1 (en) 2020-09-03
WO2017139854A1 (en) 2017-08-24
CN108697731A (zh) 2018-10-23
AU2017220396A1 (en) 2018-10-04
CA3013942C (en) 2024-03-26
AU2017220396B2 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
Comune et al. Antimicrobial peptide-gold nanoscale therapeutic formulation with high skin regenerative potential
KR102236805B1 (ko) Hc-ha/ptx3 복합체를 함유하는 조성물 및 이의 사용 방법
RU2708329C2 (ru) Материал стволовых клеток, композиции и способы применения
KR20190064745A (ko) 간엽줄기세포 유래 인공나노좀을 포함하는 폐질환 예방 또는 치료용 약학적 조성물
Authimoolam et al. Synthetic oral mucin mimic from polymer micelle networks
JP2002519331A (ja) 等張性塩水溶液の使用、同調製方法及び前記溶液をベースとする医薬
Casale et al. Hyaluronic acid and upper airway inflammation in pediatric population: a systematic review
Ammassam Veettil et al. Dextran sulfate polymer wafer promotes corneal wound healing
Li et al. Nitrogen-doped multiwalled carbon nanotubes enhance bone remodeling through immunomodulatory functions
Li et al. A 3D radially aligned nanofiber scaffold co-loaded with LL37 mimetic peptide and PDGF-BB for the management of infected chronic wounds
Sang et al. Sprayable berberine–silk fibroin microspheres with extracellular matrix anchoring function accelerate infected wound healing through antibacterial and anti-inflammatory effects
Wu et al. Colon-targeted piperine–glycyrrhizic acid nanocrystals for ulcerative colitis synergetic therapy via macrophage polarization
Li et al. Regeneration of olfactory neuroepithelium in 3-methylindole-induced anosmic rats treated with intranasal chitosan
NZ546388A (en) Lamellar bodies for therapeutic purposes
CN111617066A (zh) Chalcomoracin及其同系物在制备治疗增生性玻璃体视网膜病变药物中的应用
Tratnjek et al. Novel nasal formulation of xylometazoline with hyaluronic acid: In vitro ciliary beat frequency study
KR20180108811A (ko) 부비강 질환 및 장애의 치료를 위한 조성물 및 방법
CN103330945B (zh) 平阳霉素联合透明质酸钠在治疗淋巴管畸形药物中的应用
Lal et al. Antifungal treatment and chronic rhinosinusitis
WO2021236626A1 (en) Mucoretentive antiviral technologies
Yi et al. A Time‐Programmed Bilayer Wound Dressing for Dynamic Microenvironment Modulation and Full‐Thickness Regeneration in Diabetic Wounds
CN121059676B (zh) 苦梀叶外泌体样纳米囊泡在治疗舍格伦综合征中的应用
kai Wu et al. Hyaluronic acid methacrylate microneedles loaded with astaxanthin alleviate rheumatoid arthritis by downregulating the PI3K-AKT pathway
CN120518777A (zh) 一种豆蔻酰化Cathelicidin-DM融合Ang1-7的自组装抗菌肽及其应用
EP1667693B1 (en) Compositions and methods of using lamellar bodies for therapeutic purposes

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180906

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination